Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.
Comments Off on Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.
April 27, 2026
A new open-label study examining CBD for CDKL5 deficiency disorder treatment found 89% of patients continued therapy for 12 months. While retention rates suggest tolerability, efficacy data remains limited in this rare developmental epilepsy condition.
Baseline Characteristics and Feasibility of Clinical Outcome Measures in CDKL5 Deficiency Disorder: The CANDID Observational Study
Comments Off on Baseline Characteristics and Feasibility of Clinical Outcome Measures in CDKL5 Deficiency Disorder: The CANDID Observational Study
April 14, 2026
The CDKL5 deficiency disorder study evaluates clinical outcome measures in patients with this rare genetic condition. The CANDID observational study assesses neurodevelopmental and behavioral endpoints. This research provides insights into the…